 
|
BioRelix and Dalton Medicinal Chemistry
Expand and Renew Research Agreement to Capitalize on
RiboswitchesBioRelix, pioneers in the discovery and development of Riboswitch based therapeutic agents, and Dalton Medicinal Chemistry have jointly announced an expansion and renewal of their exclusive worldwide collaboration and agreement to discover and develop new therapeutics. New Haven, CT and Toronto, Canada (PRWEB) March 23, 2009 — BioRelix, pioneers in the discovery and development of Riboswitch based therapeutic agents, and Dalton Medicinal Chemistry have jointly announced an expansion and renewal of their exclusive worldwide collaboration and agreement to discover and develop new therapeutics. Dalton Medicinal Chemistry will apply their proprietary insights to the design and synthesis of new classes of compounds against selected Riboswitch targets. BioRelix will advance these compounds with their cutting edge array of biological assays and thorough knowledge of Riboswitch drug discovery and development. Brian Dixon, BioRelix CEO commented, "We are pleased to have the opportunity to expand and renew our productive relationship with the creative team at Dalton Medicinal Chemistry. We are confident their expertise, insights and commitment to high quality medicinal chemistry, coupled with our propriety and leading position on Riboswitches, will continue to deliver value in important new medicines." Judd Berman, Co-founder of Dalton Medicinal Chemistry, said: "We are delighted to work further with BioRelix in the discovery and development of much needed new anti-infective agents. The team at BioRelix has clearly established a remarkably innovative and fundamentally groundbreaking approach to anti-infectives and we are pleased to be with them at the forefront of this medicinal chemistry and drug discovery." |